Lymphoma and Leukaemia in Adults: What Comes After a Relapse

"We have done everything we can" usually means everything available here — which is not the same sentence

Patients arrive at this point after months of treatment, often having heard that the protocol is exhausted. That statement deserves examination. Sometimes it is clinically accurate. Sometimes it means the next line of treatment exists but is not available locally, or requires a transplant programme the hospital does not have. The distinction matters enormously, and it is worth establishing which one you are dealing with before accepting the conclusion.

1. Confirm the diagnosis before changing the treatment

Before anything else: at relapse, the disease should be re-biopsied and re-characterised. Lymphomas can transform — an indolent lymphoma can become aggressive, and the treatment for the transformed disease is entirely different. Leukaemias acquire new mutations under treatment pressure, some of which open specific targeted options.

Relapse is also the point where second opinion pathology review has the most value. Lymphoma classification is genuinely difficult and reported discrepancy rates are meaningful. Treating a relapse on the basis of a diagnosis made two years ago, without re-examining the tissue, is a mistake worth avoiding.

2. Second line treatment

For aggressive lymphoma, second line usually means salvage chemotherapy — a different combination from the first — with the goal of achieving remission and then consolidating it with autologous stem cell transplant. The salvage regimen is a bridge; the transplant is the treatment.

For leukaemia the picture depends on the type and the mutations. Some patients move to targeted agents against specific molecular abnormalities. Others go directly toward allogeneic transplant. For chronic leukaemias, changing to a different agent within the same class is often effective where resistance has developed to the first.

3. When transplant enters the discussion

Autologous transplant, using your own stem cells, is standard consolidation for relapsed aggressive lymphoma that responds to salvage therapy. Allogeneic transplant, using a donor, is used in leukaemia and in lymphoma that has failed autologous transplant, and it carries both higher risk and the possibility of long-term disease control through the donor immune response.

The critical point on donors: patients told at home that no matching donor exists have often not been assessed for haploidentical transplantation from a half-matched family member. Centres performing these routinely can offer transplant to patients previously told it was impossible. If you were told there is no donor, ask specifically whether haploidentical transplant was considered.

4. When CAR-T enters the discussion

CAR-T applies to specific B-cell malignancies — diffuse large B-cell lymphoma, follicular lymphoma, acute lymphoblastic leukaemia, multiple myeloma — in the relapsed or refractory setting, typically after two or more previous lines.

It is not a universal answer to relapse. Eligibility depends on the specific diagnosis, on what has already been tried, and on your organ function and general condition being good enough to tolerate the toxicity. A haematologist assessing you for CAR-T is assessing all three.

5. Clinical trials

At relapse, trials become a serious option rather than a last resort. They provide access to agents not yet licensed, and in haematology the pace of new drug development is fast enough that this genuinely matters.

Ask directly whether any trial is open that fits your disease and prior treatment. A haematology centre that runs trials is a centre keeping up with the field, and even if you do not enrol, the question tells you something about the department.

6. What to send for review

The complete haematology record: original diagnosis with full pathology and immunophenotyping, cytogenetics and molecular results, every treatment line with drug names, doses and dates, the response to each, current disease status, recent imaging, current blood counts and organ function tests, and HLA typing if it exists.

This is a large amount of documentation and assembling it takes days. It is also the difference between a specialist giving you a considered opinion and asking you to come back with more information. Gather it in full before you send anything.

Frequently asked questions

I was told no more treatment is available. Is that always final?
Not necessarily. It may mean no further treatment is available at that institution. Second and third line regimens, transplantation and cellular therapy exist for many relapsed haematological cancers.

Do I need a new biopsy at relapse?
Usually yes. Disease can transform or acquire new mutations under treatment, and both change what the appropriate treatment is.

How quickly can this be assessed?
With a complete record, a specialist opinion typically returns within a few working days. The delay is almost always in assembling documentation, not in the review itself.

Related reading
CAR-T Cell Therapy: Who It Is For, What It Costs and Where It Is Available
Bone Marrow Transplant in Turkey: Types, Timelines and What It Costs
Getting a Second Opinion on a Cancer Diagnosis from Another Country

This page is general information, not medical advice. Treatment options at relapse, eligibility for transplantation or cellular therapy and expected outcomes are determined individually by a licensed haematologist.